Table 2 Baseline characteristics of included studies
Study ID | Bragança et al., 2021 | Ross et al., 2020 | Pelland-Marcotte et al., 2019 | Belsky et al., 2019 | Akam-Venkata et al., 2018 | Ji et al., 2019 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sample size | 29 | 33 | 170 | 8 | 9 | 9 | |||||||||
Exposure group | NMPE | SMPE | MPE | SMPE | MPE | NMPE | SMPE + MPE | SMPE | Total (SMPE + MPE) | SMPE | MPE | Total (SMPE + MPE) | SMPE | MPE | |
n (%) | 13 | 11 | 5 | 24 | 9 | 121 | 49 | 6 | 9 | 6 | 3 | 9 | 4 | 5 | |
Age Median (IQR) | - | - | - | 15(15–16) | 16(10–16) | 14·5 (9·3–16·1) | 12·5 (0·6–15·1) | 15 (3–21) | 16 (12–20) | - | - | 13.9 (4.38) | - | - | |
Females n (%) | 6(46.2%) | 9(81.8%) | 2(40%) | 17(71) | 5(56) | 52 (43%) | 29 (59%) | 2 (30%) | 6 (66.67%) | 3 (50%) | 3 (100%) | 5 (55%) | - | - | |
PE location n (%) | Bilateral | - | - | - | - | - | 46 (39%) | 34 (69%) | - | - | - | - | - | - | - |
Lobar | - | - | - | - | - | 63 (53%) | 35 (71%) | - | - | - | - | - | - | - | |
Segmental | - | - | - | - | - | 43 (36%) | 10 (20%) | - | - | - | - | - | - | - | |
Subsegmental | - | - | - | - | - | 13 (11%) | 4 (8%) | - | - | - | - | - | - | - | |
Clinical presentation n (%) | None | - | - | - | - | - | 21 (17%) | 2 (4%) | - | - | - | - | - | - | |
Dyspnoea (SOB) | - | - | - | - | - | 64 (53%) | 28 (57%) | 3 (50%) | 9 (100%) | - | - | 1 (10%) | - | - | |
Chest pain | - | - | - | - | - | 63 (52%) | 9 (18%) | 6 (100%) | - | - | - | - | - | - | |
Haemoptysis | - | - | - | - | - | 7 (6%) | 4 (8%) | - | - | - | - | - | - | - | |
Cyanosis or hypoxemia | 5(38.5%) | 4(36.4%) | 5(100%) | 13 (11%) | 33 (67%) | - | 9 (100%) | - | - | - | - | - | |||
Shock or cardiac arrest | 0 | 0 | 1(20%) | 0 | 4(44) | 4 (3%) | 21 (43%) | - | - | - | - | - | - | - | |
Syncope | 2(15.4%) | 3(27.3%) | 1(20%) | - | - | - | - | 2 (30%) | - | - | - | - | - | - | |
Tachycardia/ palpitation | 3(23.1%) | 10(90.9%) | 5(100%) | - | - | - | - | 1 (16%) | - | - | - | - | - | - | |
Leg pain or DVT | - | - | - | - | - | - | - | 1 (16%) | 5 (56%) | 2 (33%) | 2 (66%) | 3 (33%) | |||
Vasopressor requirement | - | - | - | 1 (50) | 5(56) | - | - | - | - | - | - | - | - | - | |
Major Comorbidities n (%) | - | - | - | 6(25) | 8(89) | - | - | - | - | - | - | - | - | - | |
D-dimer: Negative n (%) | 2(15.4%) | - | 0 | - | - | - | - | - | - | - | - | - | - | - | |
Thrombophilia: Negative n (%) | - | - | - | - | - | 53/90 (59%) | 15/28 (53%) | 4 (66%) | - | - | - | - | - | - | |
Diagnostic method n (%) | CT | - | - | - | 23(96) | 2(22) | - | - | 6 (100%) | 9 (100%) | 6 (100%) | 3 (100%) | - | - | - |
Angiography | - | - | - | 0 | 5(56) | - | - | - | - | - | - | - | - | - | |
Ventilation or perfusion scan | - | - | - | 1(4) | 0 | - | - | - | - | - | - | - | - | - | |
Autopsy | - | - | - | 0 | 2(22) | - | - | - | - | - | - | - | - | - | |
Management n (%) | Anticoagulation only | 12(92.3%) | 8(72.7%) | 0 | 24(100) | 7(78) | 106 (88%) | 23 (47%) | - | - | - | - | - | - | - |
Any reperfusion (aggressive therapy) | - | - | - | 16(67) | 7(78) | 7 (6%) | 22 (45%) | - | - | - | - | - | - | - | |
Surgical embolectomy | - | - | - | 2 (13) | 3 (43) | - | - | - | - | - | - | - | - | - | |
Catheter-directed therapy | - | - | - | 1 (6) | 3 (43) | - | - | 6 (100%) | 9 (100%) | 6 (100%) | 3 (100%) | 9 (100%) | 6 (100%) | 3 (100%) | |
Systemic thrombolysis | - | - | - | 13 (81) | 1 (14) | - | - | - | - | - | - | - | - | - | |
Observation | - | - | - | - | - | 8 (7%) | 4 (8%) | - | - | - | - | - | - | ||
PICU admission | 2(15.4%) | 2(18.2%) | 4(100%) | - | - | - | - | - | - | - | - | - | - | - | |